Radionuclide-antibody conjugates for single-cell cytotoxicity

Cancer

Volumn 94, Issue 4 SUPPL., 2002, Pages 1215-1223

  Mattes, M Jules ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

Antibody mediated cytotoxicity; Auger electron emitters; Radioimmunotherapy; Radiolabeled antibodies

Indexed keywords

ANTIBODY CONJUGATE; ASTATINE 211; BISMUTH; BISMUTH 212; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GALLIUM 67; INDIUM 111; IODINE 125; IODINE 131; MERCURY; MERCURY 195; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD74 GA 67; OSMIUM; OSMIUM 191; PENTETREOTIDE IN 111; PLATINUM; PLATINUM 193M; PLATINUM 195M; RADIOISOTOPE; SAMARIUM 153; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90; PLATINUM 193; PLATINUM 195;

ALPHA RADIATION; CELL LEVEL; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG UPTAKE; ELECTRON RADIATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; ANTIGEN BINDING; AUGER ELECTRON SPECTROSCOPY; CELL KILLING; CELL SURFACE; CYTOPLASM; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG POTENCY; ELECTRON; INTERNALIZATION; ISOTOPE LABELING; MICROMETASTASIS; RADIOIMMUNOTHERAPY; SINGLE CELL ANALYSIS; TUMOR VOLUME;

EID: 0037083401     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10288     Document Type: Conference Paper

References (54)

1. Electron dosimetry for radioimmunotherapy: Optimal electron energy
2. Multicellular dosimetry for micrometastases: Dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides
3. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
4. Modeling analysis of platinum-195m for targeting individual blood-borne cells in adjuvant radioimmunotherapy
5. Radioimmunotherapy of human colonic cancer xenografts with 90Y-labeled monoclonal antibodies to carcinoembryonic antigen
6. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)
7. 131I-labeled CO17-1A in a human colorectal cancer model
8. Radionuclide toxicity in cultured mammalian cells: Elucidation of the primary site of radiation damage
9. Bismuth-212-labeled anti-TAC monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy
10. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry
11. An improved generator for the production of Bi-212 from Ra-224
12. 213Bi
13. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia
14. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer
15. 211At produced in disposable internal and external bismuth targets
16. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labeling of N-succinimidyl 3-(trimethylstannyl)benzoate
17. Radiation spectra for Auger-electron emitting radionuclides. Report No. 2 of AAPM Nuclear Medicine Task Group No. 6
18. Absorption of 20 eV to 50,000 eV electron beams in air and plastic
19. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: Comparison of Auger electron emitters with β-particle emitters
20. Selective chromosomal damage and cytotoxicity of 1251 -labeled monoclonal antibody 17-1a in human cancer cells
21. SCLC-cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
22. Single-cell cytotoxicity with radiolabeled antibodies
23. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody
24. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies
25. 90Y
26. The fate of antibodies bound to the surface of tumor cells in vitro
27. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors
28. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
29. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer
30. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs
31. Peptide receptor imaging and therapy
32. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
33. Pharmacokinetics and biodistribution of samarium-153-labeled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer
34. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates
35. An approach for immunoradiometric assay with metallic radionuclides: Gallium-67-deferoxamine-dial-dehyde starch-IgG
36. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
37. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
38. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor
39. 125I-labeled anti-gp160 monoclonal antibody
40. 125I-labeled 9.2.27 monoclonal antibody
41. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas
42. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission
43. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
44. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats
45. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
46. 125I-labeled DNA intercalator in mammalian cells
47. Patterns of antigen distribution in human carcinomas
48. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial fluid pressure
49. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: The influence of administered MAb dose on tumor uptake
50. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice
51. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer
52. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete response